Can a Reduction in Substance Use Improve Psychiatric Outcomes among Individuals with Co-Occurring Psychiatric and Substance Use Disorders?
Christian J. Teter, PharmD, BCPP
Assistant Professor of Psychiatric Pharmacy, College of Pharmacy, University of New England
Disclosures: Discussion of off-label uses (using products for a purpose other than that for which it was approved by the Food and Drug Administration, or FDA) will occur during this presentation. The speaker has no conflicts of interest to disclose. The activity planners have no conflicts of interest to disclose.
Upon completion of this presentation, the participant will be able to:
1. Describe the prevalence rate of substance use disorders that co-occur among various Axis I psychiatric disorders.
2. Recognize the elevated morbidity and mortality associated with co-occurring psychiatric and substance use disorders.
3. Select psychiatric outcomes that have been shown to respond to improvements in co-occurring substance use.
Continuing Nursing Education
1.5 contact hours, upon completion of a post-test and evaluation. * In order to receive contact hours, you must: Listen to the entire session, complete an evaluation, and earn a passing score on the post test before the expiration date. You will have 5 tries to earn a score of 80% or better on the post test. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. We cannot award credit unless all steps are completed.
The content of this CNE activity pertains to pharmacology. Because states' requirements may vary, contact your Board of Nursing for more information.
The American Psychiatric Nurses Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
June 26, 2010
Hyatt Regency Reston
Release Date: August 23, 2010
The contact hours for this session expire: July 1, 2013